Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

116 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-14

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Limb Girdle Muscular Dystrophy comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. While the individual genetic mutations are rare, as a cohort, LGMDs are one of the four most common muscular dystrophies. The overall goal of project 1 is to define the key phenotypes as measured by standard clinical outcome assessments (COAs) for limb girdle muscular dystrophies (LGMD) to hasten therapeutic development.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MRI and Muscle Involvement in Patients With Mutations in GMPPB

NCT02635321

Limb-girdle Muscular Dystrophy

COMPLETED

Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy

NCT00457912

Limb-Girdle Muscular Dystrophy

COMPLETED

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

NCT01568658

Muscular Dystrophies Muscle Myopathies Hereditary Spastic Paraplegias +2 more

RECRUITING

Phenotype/Genotype Correlations in Neuromuscular Disorders

NCT00017745

Neuromuscular Disease

COMPLETED

Genetics of Primary Ciliary Dyskinesia

NCT02389049

Primary Ciliary Dyskinesia Kartagener Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The genetic heterogeneity has been a barrier to broad natural history efforts, with prior investigations often limited to single gene mutations. Much attention is paid to the variability within individual mutations (e.g. distal presentations), as opposed to defining the best strategy for measuring change in overall LGMD disease burden. This presents a major dilemma for LGMD rare disease research: how to balance diverse genes leading to overlapping phenotypes, versus variants in the same gene leading to divergent phenotypes. What is clear, is as a group, LGMDs are chronic and progressive leading to significant lifetime morbidity and represent a large unmet clinical need.

Recent developments in the investigator's genetic understanding of LGMD and molecular approaches to therapy have led to proposed gene replacement therapies for at least three of the LGMD mutations. Several of these gene replacement therapies are currently in pre-clinical/phase 1 testing, leading to an urgent need for natural history data. In addition, non-specific therapies which target muscle mass or function are being tested in other muscular dystrophies and may prove beneficial for LGMD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Limb Girdle Muscular Dystrophy Muscular Dystrophies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.